Texas Institute for Genomic Medicine Receives Second Installation of OmniBank® II Library
News Jan 29, 2007
The Texas Institute for Genomic Medicine (TIGM) has announced that the second installation of its OmniBank II library of knockout mouse embryonic stem cell clones has been completed by Lexicon Genetics Incorporated.
The second installation contains more than 100,000 clones, bringing the total number of clones to more than 200,000 contained in TIGM’s OmniBank II library.
Each clone represents an embryonic stem cell line generated in the C57BL/6 mouse genetic background in which a single gene has been disrupted, or knocked out.
More than 8,200 distinct genes are currently included in the library and can be accessed by researchers worldwide as breeding pairs of knockout mice.
TIGM’s OmniBank II library is now expected to be completed in the third quarter of 2007, well ahead of schedule. When complete, the library will be comprised of 350,000 mouse embryonic stem cell clones.
The library is located at TIGM’s facilities in Houston’s Texas Medical Center. Construction is underway of new facilities in College Station, Texas, to house one copy of the library and mouse breeding facilities, with completion expected in the third quarter of 2007.
“In less than 18 months, the Texas Institute for Genomic Medicine has amassed a huge resource of knockout mice for use in therapeutic discovery by researchers worldwide,” said Richard H. Finnell, Ph.D., executive director and president of the Texas Institute for Genomic Medicine.
“The cell lines in our OmniBank II library have been engineered to enable researchers to study the involvement of specific genes in a wide variety of diseases and conditions. We believe the research potential of OmniBank II will prove to be very important in the advancement of human and veterinary health.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.